Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · IEX Real-Time Price · USD
63.37
+2.05 (3.34%)
At close: May 1, 2024, 4:00 PM
62.00
-1.37 (-2.16%)
After-hours: May 1, 2024, 7:17 PM EDT
Cytokinetics Employees
Cytokinetics had 423 employees on December 31, 2023. The number of employees increased by 14 or 3.42% compared to the previous year.
Employees
423
Change (1Y)
14
Growth (1Y)
3.42%
Revenue / Employee
$17,801
Profits / Employee
-$1,244,076
Market Cap
6.63B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 423 | 14 | 3.42% |
Dec 31, 2022 | 409 | 156 | 61.66% |
Dec 31, 2021 | 253 | 69 | 37.50% |
Dec 31, 2020 | 184 | 28 | 17.95% |
Dec 31, 2019 | 156 | 26 | 20.00% |
Dec 31, 2018 | 130 | -7 | -5.11% |
Dec 31, 2017 | 137 | 10 | 7.87% |
Dec 31, 2016 | 127 | 27 | 27.00% |
Dec 31, 2015 | 100 | 8 | 8.70% |
Dec 31, 2014 | 92 | 7 | 8.24% |
Dec 31, 2013 | 85 | 15 | 21.43% |
Dec 31, 2012 | 70 | -9 | -11.39% |
Dec 31, 2011 | 79 | -26 | -24.76% |
Dec 31, 2010 | 105 | -6 | -5.41% |
Dec 31, 2009 | 111 | 1 | 0.91% |
Dec 31, 2008 | 110 | -51 | -31.68% |
Dec 31, 2007 | 161 | 13 | 8.78% |
Dec 31, 2006 | 148 | -2 | -1.33% |
Dec 31, 2005 | 150 | -20 | -11.76% |
Dec 31, 2004 | 170 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
The Ensign Group | 35,300 |
DENTSPLY SIRONA | 15,000 |
Elanco Animal Health | 9,800 |
Globus Medical | 5,000 |
HealthEquity | 3,150 |
Ionis Pharmaceuticals | 927 |
Blueprint Medicines | 655 |
ImmunityBio | 628 |
CYTK News
- 2 days ago - Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress - GlobeNewsWire
- 7 days ago - Cytokinetics to Announce First Quarter Results on May 8, 2024 - GlobeNewsWire
- 21 days ago - This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives? - Market Watch
- 21 days ago - Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress - GlobeNewsWire
- 26 days ago - Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session - GlobeNewsWire
- 4 weeks ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session - GlobeNewsWire